Evidence map›Paper›PMID 38076012›Full record

ArticleClinical case reports2023

Transformation of a long-standing phosphaturic tumor-inducing osteomalacia into malignancy.

Jose Malagon-Rangel, Jose Gabriel Solis, Luis Fernando Zavala-Jonguitud, Martín Roberto Basile-Alvarez, Andrea Malagon-Liceaga

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jose Malagon-RangelInternal Medicine Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social Mexico City Mexico.ORCID https://orcid.org/0000-0002-3564-0054
Jose Gabriel SolisInternal Medicine Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social Mexico City Mexico.ORCID https://orcid.org/0000-0003-3532-6062
Luis Fernando Zavala-JonguitudInternal Medicine Department, Hospital de Especialidades, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social Mexico City Mexico.ORCID https://orcid.org/0000-0002-6405-7810
Martín Roberto Basile-AlvarezPhysiology Department, Faculty of Medicine National Autonomous University of Mexico Mexico City Mexico.ORCID https://orcid.org/0000-0003-0078-9710
Andrea Malagon-LiceagaPhysiology Department, Faculty of Medicine National Autonomous University of Mexico Mexico City Mexico.ORCID https://orcid.org/0000-0002-7617-3915
Mexican Social Security Institute · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key Clinical Message: Tumor-induced osteomalacia is a paraneoplastic syndrome characterized by renal phosphate wasting and deranged bone turnover. Clinicians should consider tumor-induced osteomalacia in unexplained hypophosphatemia and investigate for underlying tumors. Abstract: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, which leads to deranged bone turnover. TIO is usually associated with benign mesenchymal tumors, although it has also been reported in malignant tumors. We present the case of a 56-year-old individual who experienced a protracted 6-year clinical course characterized by hypophosphatemia, weakness, and kyphosis, alongside the presence of a foot tumor. Subsequently, this lesion displayed malignant behavior and was ultimately diagnosed as a high-grade sarcoma. To date, this case is among the 10 reported cases in the literature of a mesenchymal tumor associated with TIO undergoing malignant transformation. This report underscores the importance of a comprehensive evaluation of patients with unexplained hypophosphatemia and highlights the need for diligent follow-up to detect possible malignant transformation of the underlying tumor. Clinicians should consider TIO in the differential diagnosis of hypophosphatemia and promptly investigate for the presence of an underlying tumor, as early detection may improve the patient's prognosis.

Indexed as

case reportsoncogenic osteomalaciaparaneoplastic syndromesricketssarcoma

Identifiers

PMID38076012
PMCPMC10697852
OpenAlexW4389356555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.